PERSEUS Supports D-VRd Followed by DR Maintenance as New SOC in MM

Paula Rodriguez-Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, discusses the promising results from the phase 3 PERSEUS trial (NCT03710603), a randomized, interventional, open-label, study comparing subcutaneous daratumumab (Darzalex) followed by autologous stem cell transplant (ASCT) and daratumumab, bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) consolidation and daratumumab/lenalidomide maintenance in patients with newly diagnosed, transplant-eligible multiple myeloma.

According to Otero, this regimen significantly prolonged the rates of progression-free survival (PFS) in this patient population. At a median follow-up of 47.5 months, the 4-year PFS rate observed among patients treated with D-VRd was 84.3% vs 67.7% with VRd. This led to a 58% reduction in the risk of disease progression or death with the addition of the CD38 monoclonal antibody (HR, 0.42; 95% CI, 0.30-0.59; P <.0001). Further, the overall rate of complete response or better (≥CR) was 87.9% with D-VRd vs 70.1% with VRd (P <.0001).

These findings will likely change the standard of care for the treatment of patients with newly diagnosed multiple myeloma.

Transcription:

0:09 | This is a late breaker and also the 1 of the most relevant abstracts that was presented [at the 2023 ASH Annual Meeting] because this probably [and] clearly will change the standard of care for treatment of [patients with] newly diagnosed multiple myeloma that are candidates for transplant. The results presented by Dr. Sonneveld were very impressive, mostly because of the high rates of minimal residual disease in the D-VRd treatment arm.

0:43 | [This also led] to an improvement in PFS in these patients, and these are probably 1 of the higher rates of MRD negativity shown in the setting of the newly diagnosed frontline and transplant eligible candidates. I think that this is a very important abstract, a very important paper, and a very important treatment to give to all of our [patients with] newly diagnosed transplant eligible myeloma.

REFERENCE

Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Phase 3 randomized study of daratumumab + bortezomib, lenalidomide, and dexamethasone (VRd) versus VRd alone in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: primary results of the PERSEUS trial. Blood. 2023;142(suppl 2):LBA1. doi:10.1182/blood-2023.191911